ClinicalTrials.gg
TerminatedNCT02020278Updated Apr 17, 2020Results posted

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

A Phase 3 interventional study of Tolvaptan in Hyponatremia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 23 sites in 8 countries. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2020-04-17.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Issues with recruitment and enrollment made the trial impossible or highly impracticable. Termination of this trial was not due to safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
4 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.

Enrollment
17th of 20
3 · median 55
Started
2016
with 2 others
Phase 3
9 of 20
none open now
Registered
15th of 20
by date
Lead sponsor
8 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 17th largest by enrollment, is one of 3 that started in 2016, is one of 9 in phase 3, and was the 15th registered.

Hyponatremia

164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.

Browse Hyponatremia studies →

Open to participants now

None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 4 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing tolvaptan in Hyponatremia as a file.
02

Study summary

The objective of this trial was to provide 6 months of safety follow-up for children and adolescents with dilutional (euvolemic or hypervolemic) hyponatremia who had previously participated in a tolvaptan hyponatremia trial and to assess the efficacy of tolvaptan in increasing serum sodium for those participants who received optional continuing tolvaptan treatment of variable duration (up to 6 months).

Read the detailed description

Core Safety Follow-up Component

  • For all participants: To evaluate the post-treatment safety follow-up of children and adolescent participants with dilutional (euvolemic or hypervolemic) hyponatremia who have previously participated in a tolvaptan hyponatremia trial.

Optional Tolvaptan Treatment Component

  • For participants who receive optional tolvaptan treatment: To demonstrate that tolvaptan safely and effectively achieves and maintains increased serum sodium concentrations in children and adolescent participants with dilutional (euvolemic or hypervolemic) hyponatremia when used for both multiple short-term treatments, and/or longer chronic treatments.
03

Conditions studied

  • Hyponatremia

Keywords

  • Hyponatremia
  • Euvolemic
  • Hypervolemic
  • Serum sodium
  • Dilutional hyponatremia
  • Electrolyte abnormality
  • Electrolyte imbalance
  • Metabolic disease
  • Water-Electrolyte Imbalance
04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Core Safety Follow-up Component

Inclusion Criteria: Participation in a prior pediatric trial with tolvaptan for euvolemic or hypervolemic hyponatremia.

Exclusion Criteria: None

Optional Tolvaptan Treatment Component (per treatment cycle)

Eligibility Criteria:

  1. Male and female participants ≥ 4 years of age (or per local Health Authority age restrictions) and ≥ 10 kilograms (kg).
  2. Participant must have been off treatment with the medicinal product for at least 7 days following the end of treatment in the previous tolvaptan trial for hyponatremia (euvolemic or hypervolemic).
  3. Persistent dilutional (euvolemic or hypervolemic) hyponatremia defined as being documented as present for at least 48 hours, evidenced by at least 2 serum sodium assessments \< 130 milliequivalents (mEq)/liter (L) (millimole [mmol]/L) drawn at least 12 hours apart (these values can be documented using historical values previously obtained per standard of care); a third (STAT) serum sodium assessment \< 130 mEq/L (mmol/L), which will serve as the baseline value for efficacy endpoints, had to be obtained within 2 to 4 hours prior to the first dose of tolvaptan.
  4. Ability to swallow tablets.
  5. Ability to maintain adequate fluid intake whether orally or via intravenous support with adequate monitoring.
  6. Ability to comply with all requirements of the trial.
  7. Trial-specific written /assent obtained from a parent/legal guardian or legally acceptable representative, as applicable per age of participant or local laws, prior to the initiation of any protocol-required procedures. In addition, the participant as required by local laws must provide informed assent at the pretreatment baseline for this trial and must be able to understand that he or she can withdraw from the trial at any time. All informed consent/assent procedures must be in accordance with the trial center's Institutional Review Board/Independent Ethics Committee and local regulatory requirements.
  8. Ability to commit to remain fully abstinent (periodic abstinence [for example, calendar, ovulation, symptothermal, post-ovulation methods] or withdrawal are not acceptable methods of ) or practice double-barrier birth control during the trial and for 30 days following the last dose of IMP for sexually active females of .

Ineligibility Criteria:

  1. Had evidence of hypovolemia or intravascular volume depletion (for example, hypotension, clinical evidence of volume depletion, response to saline challenge); if the participant had systolic blood pressure or heart rate outside of the normal range for that age, then volume status was to be specifically clinically assessed to rule out volume depletion.
  2. Had serum sodium \< 120 mEq/L (mmol/L), with or without associated neurologic impairment (that is, symptoms such as apathy, confusion, or seizures).
  3. Use of potent inhibitors in participants ≤ 50 kg or moderate CYP3A4 inhibitors in participants \< 20 kg.
  4. Lacked free access to water (inability to respond to thirst) or without ICU-level fluid monitoring and management.
  5. Had a history or current diagnosis of nephrotic syndrome.
  6. Had transient hyponatremia likely to resolve (for example, head trauma or post-operative state).
  7. Had hyperkalemia defined as serum potassium above the (ULN) for the appropriate pediatric age range.
  8. Had estimated (eGFR) \< 30 milliliters (mL)/minute (min)/1.73 meters squared (m\^2) calculated by the following equation: eGFR (mL/min/1.73 m\^2) = 0.413 x height (centimeter [cm])/serum creatinine (mg/deciliter [dL]).
  9. Had acute kidney injury defined as: Increase in serum creatinine by ≥ 0.3 mg/dL (≥ 26.5 micromoles [μmol]/L) within 48 hours; or increase in serum creatinine to ≥ 1.5 times baseline, which was known or presumed to have occurred within the prior 7 days; or urine volume \< 0.5 mL/kg/hour for 6 hours.
  10. Had severe or acute neurological symptoms requiring other intervention (for example, hyperemesis, obtundation, seizures).
  11. Had had treatment for hyponatremia with:

    • Hypertonic saline (including normal saline challenge) within 8 hours of qualifying sodium assessments;
    • Urea, lithium, demeclocycline, conivaptan, or tolvaptan within 4 days of qualifying serum sodium assessments;
    • Other treatment for the purpose of increasing serum sodium concurrent with dosing of trial medication
  12. Had anuria or urinary outflow obstruction, unless the participant was, or could be, catheterized during the trial.
  13. Had a history of drug or medication abuse within 3 months prior to the pretreatment visit or current alcohol abuse.
  14. Had a history of and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril).
  15. Had psychogenic polydipsia (participants with other psychiatric illness may be included per medical monitor approval).
  16. Had uncontrolled diabetes mellitus, defined as fasting glucose > 300 mg/dL (16.7 mEq/L [mmol/L]).
  17. Had screening liver function values > 3 x ULN.
  18. Had cirrhosis and met any of the following conditions: a major gastrointestinal bleed within the past 6 months, evidence of active bleeding (for example, epistaxis, petechiae/purpura, hematuria, or hematochezia), count \< 50,000/μL, or use of concomitant medications known to increase bleeding risk.
  19. Had hyponatremia due to the result of any medication that can safely be withdrawn (for example, thiazide diuretics).
  20. Had hyponatremia (for example, hyponatremia in the setting of adrenal insufficiency, untreated hypothyroidism, or hypotonic fluid administration) that is most appropriately corrected by alternative therapies.
  21. Was currently pregnant or breastfeeding.
  22. Had any medical condition that, in the opinion of the investigator, could interfere with evaluation of the trial objectives or safety of the participants.
  23. Was deemed unsuitable for trial participation in the opinion of the investigator.
  24. Participation in another investigational drug trial within the past 30 days, without prior approval from the sponsor medical monitor.
  25. Participants \< 4 years of age (or per local Health Authority age restrictions), weight \< 10 kg, or who were unable to swallow tablets.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Tolvaptan

    Participants enrolled in this trial were eligible to receive open-label tolvaptan if they had a clinical need as determined by the investigator and met the eligibility criteria for optional tolvaptan treatment. Daily dose levels would have included 3.75 milligrams (mg), 7.5 mg, 15 mg, 30 mg, and 60 mg.

    Drug: Tolvaptan

Interventions

  • Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily. Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period.

    Also known as: SAMSCA®

06

What researchers measure

Primary outcomes

  1. Change From Baseline At Month 6 In Serum Sodium While Tolvaptan Was Being Administered

    No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Percentage Of Participants Who Required Rescue Therapy While On Tolvaptan Treatment

    No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

    Time frame: Month 6

  2. Percentage Of Participants Who Had Recurrence Of Hyponatremia While On Tolvaptan

    No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

    Time frame: Month 6

  3. Percentage Of Participants Requiring Continuation Of Tolvaptan Following 30 Days Of Treatment

    No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

    Time frame: Month 6

  4. Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Total Score At Month 6

    The PedsQL GCS was used for quality of life assessment. It is appropriate for at least 2 years of age, however availability may be limited for certain ages and languages. It encompasses 4 dimensions of functioning (physical, emotional, social, school). The age groups covered are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Adolescent (13-18 years). Depending on the participant's age, the questionnaire may be completed by either the participant or the parent/caregiver, as appropriate. For the Toddler group, the PedsQL GCS consists of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consists of 23 items, with a 3-point Likert scale (0, 2, 4) for the Young Child, and a 5-point Likert scale for the Child and Adolescent groups. Scores are transformed on a scale from 0 to 100 and averaged. Higher scores indicate improved quality of life. The change from baseline in the GCS total score is presented.

    Time frame: Baseline, Month 6

  5. Change From Baseline In PedsQL GCS Physical Health Summary Score At Month 6

    The PedsQL GCS was used for quality of life assessment. It is appropriate for at least 2 years of age, however availability may be limited for certain ages and languages. It encompasses 4 dimensions of functioning (physical, emotional, social, school). The age groups covered are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Adolescent (13-18 years). Depending on the participant's age, the questionnaire may be completed by either the participant or the parent/caregiver, as appropriate. For the Toddler group, the PedsQL GCS consists of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consists of 23 items, with a 3-point Likert scale (0, 2, 4) for the Young Child, and a 5-point Likert scale for the Child and Adolescent groups. Scores are transformed on a scale from 0 to 100 and averaged. Higher scores indicate improved quality of life. The change from baseline in the physical health dimension is presented.

    Time frame: Baseline, Month 6

  6. Change From Baseline In PedsQL GCS Psychosocial Health Summary Score At Month 6

    The PedsQL GCS was used for quality of life assessment. It is appropriate for at least 2 years of age, however availability may be limited for certain ages and languages. It encompasses 4 dimensions of functioning (physical, emotional, social, school). The age groups covered are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Adolescent (13-18 years). Depending on the participant's age, the questionnaire may be completed by either the participant or the parent/caregiver, as appropriate. For the Toddler group, the PedsQL GCS consists of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consists of 23 items, with a 3-point Likert scale (0, 2, 4) for the Young Child, and a 5-point Likert scale for the Child and Adolescent groups. Scores are transformed on a scale from 0 to 100 and averaged. Higher scores indicate improved quality of life. The change from baseline in summed emotional, social, and school dimensions is presented.

    Time frame: Baseline, Month 6

  7. Change From Baseline In PedsQL Multidimensional Fatigue Scale (MFS) Total Score At Month 6

    The PedsQL GCS was used for quality of life assessment. It is appropriate for at least 2 years of age, however availability may be limited for certain ages and languages. It encompasses 4 dimensions of functioning (physical, emotional, social, school). The age groups covered are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Adolescent (13-18 years). Depending on the participant's age, the questionnaire may be completed by either the participant or the parent/caregiver, as appropriate. For the Toddler group, the PedsQL GCS consists of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consists of 23 items, with a 3-point Likert scale (0, 2, 4) for the Young Child, and a 5-point Likert scale for the Child and Adolescent groups. Scores are transformed on a scale from 0 to 100 and averaged. Higher scores indicate improved quality of life. The change from baseline in summed emotional, social, and school dimensions is presented.

    Time frame: Baseline, Month 6

  8. Percentage Of Participants With Overly Rapid Correction In Serum Sodium 24 Hours After The First Dose At Introduction Or Reintroduction Of Tolvaptan

    No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

    Time frame: Month 6

  9. Plasma Concentrations Of Tolvaptan And Metabolites In Participants Who Had Continued Tolvaptan Therapy For Eight Consecutive Weeks

    No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

    Time frame: 8 Weeks

  10. Participants With A Tanner Staging Score Of 1 At Month 6

    Tanner Staging assessment consists of 2 domains (pubic hair and breast development) for girls and 3 domains (pubic hair, penis development, and testes development) for boys. Staging was based on a single score summarizing the domains (not individual domain scores). Stages range from 1-5, with 1 indicating preadolescent and 5 adult. Participants with a Tanner staging score of 1 (preadolescent) at Month 6 are reported.

    Time frame: Month 6

  11. Change From Baseline In Growth Percentiles For Body Height And Weight At Month 6

    Changes from baseline in growth percentiles for body height and weight were calculated and are reported.

    Time frame: Baseline, Month 6

  12. Change From Baseline In Alanine Aminotransferase (ALT) And Aspartate Aminotransferase (AST) For Participants On Tolvaptan At Month 2

    No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected. Data reported only include assessments made for ALT and AST during the Core Safety Follow-up Component of the trial. Results are reported in units/liter (U/L).

    Time frame: Baseline, Month 2

  13. Change From Baseline In Bilirubin For Participants On Tolvaptan At Month 2

    No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected. Data reported only include assessments made for bilirubin during the Core Safety Follow-up Component of the trial. Results are reported in micromoles (umol)/L.

    Time frame: Baseline, Month 2

07

Results

Posted Apr 17, 2020
Limitations and caveats
This trial was prematurely terminated due to challenges in enrollment. The trial was not terminated due to safety reasons. Due to early termination of the study, no efficacy data were collected.

Participant flow

Eligible participants included those enrolled in a previous tolvaptan pediatric trial for hyponatremia (NCT02012959); who provided written informed consent at baseline and were able to understand that he/she could withdraw at any time; with the ability to comply with all requirements of the trial; ready to be followed up for 6 months.

Core Safety Follow-up Component
Participant flow — Core Safety Follow-up Component
MilestoneTolvaptan
Started3
Completed3
Not completed0
Optional Tolvaptan Treatment Component
Participant flow — Optional Tolvaptan Treatment Component
MilestoneTolvaptan
Started0
Completed0
Not completed0

Outcome measures

PrimaryChange From Baseline At Month 6 In Serum Sodium While Tolvaptan Was Being Administered

No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

Time frame:
Baseline, Month 6

No measurements were reported for this outcome.

SecondaryPercentage Of Participants Who Required Rescue Therapy While On Tolvaptan Treatment

No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryPercentage Of Participants Who Had Recurrence Of Hyponatremia While On Tolvaptan

No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryPercentage Of Participants Requiring Continuation Of Tolvaptan Following 30 Days Of Treatment

No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryChange From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Total Score At Month 6

The PedsQL GCS was used for quality of life assessment. It is appropriate for at least 2 years of age, however availability may be limited for certain ages and languages. It encompasses 4 dimensions of functioning (physical, emotional, social, school). The age groups covered are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Adolescent (13-18 years). Depending on the participant's age, the questionnaire may be completed by either the participant or the parent/caregiver, as appropriate. For the Toddler group, the PedsQL GCS consists of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consists of 23 items, with a 3-point Likert scale (0, 2, 4) for the Young Child, and a 5-point Likert scale for the Child and Adolescent groups. Scores are transformed on a scale from 0 to 100 and averaged. Higher scores indicate improved quality of life. The change from baseline in the GCS total score is presented.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Total Score At Month 6
units on a scaleCore Safety Follow-up Component
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Total Score At Month 6-3.5 (-3.5 to -3.5)
SecondaryChange From Baseline In PedsQL GCS Physical Health Summary Score At Month 6

The PedsQL GCS was used for quality of life assessment. It is appropriate for at least 2 years of age, however availability may be limited for certain ages and languages. It encompasses 4 dimensions of functioning (physical, emotional, social, school). The age groups covered are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Adolescent (13-18 years). Depending on the participant's age, the questionnaire may be completed by either the participant or the parent/caregiver, as appropriate. For the Toddler group, the PedsQL GCS consists of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consists of 23 items, with a 3-point Likert scale (0, 2, 4) for the Young Child, and a 5-point Likert scale for the Child and Adolescent groups. Scores are transformed on a scale from 0 to 100 and averaged. Higher scores indicate improved quality of life. The change from baseline in the physical health dimension is presented.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline In PedsQL GCS Physical Health Summary Score At Month 6
units on a scaleCore Safety Follow-up Component
Change From Baseline In PedsQL GCS Physical Health Summary Score At Month 612.5 (12.5 to 12.5)
SecondaryChange From Baseline In PedsQL GCS Psychosocial Health Summary Score At Month 6

The PedsQL GCS was used for quality of life assessment. It is appropriate for at least 2 years of age, however availability may be limited for certain ages and languages. It encompasses 4 dimensions of functioning (physical, emotional, social, school). The age groups covered are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Adolescent (13-18 years). Depending on the participant's age, the questionnaire may be completed by either the participant or the parent/caregiver, as appropriate. For the Toddler group, the PedsQL GCS consists of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consists of 23 items, with a 3-point Likert scale (0, 2, 4) for the Young Child, and a 5-point Likert scale for the Child and Adolescent groups. Scores are transformed on a scale from 0 to 100 and averaged. Higher scores indicate improved quality of life. The change from baseline in summed emotional, social, and school dimensions is presented.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline In PedsQL GCS Psychosocial Health Summary Score At Month 6
units on a scaleCore Safety Follow-up Component
Change From Baseline In PedsQL GCS Psychosocial Health Summary Score At Month 6-13.5 (-13.5 to -13.5)
SecondaryChange From Baseline In PedsQL Multidimensional Fatigue Scale (MFS) Total Score At Month 6

The PedsQL GCS was used for quality of life assessment. It is appropriate for at least 2 years of age, however availability may be limited for certain ages and languages. It encompasses 4 dimensions of functioning (physical, emotional, social, school). The age groups covered are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Adolescent (13-18 years). Depending on the participant's age, the questionnaire may be completed by either the participant or the parent/caregiver, as appropriate. For the Toddler group, the PedsQL GCS consists of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consists of 23 items, with a 3-point Likert scale (0, 2, 4) for the Young Child, and a 5-point Likert scale for the Child and Adolescent groups. Scores are transformed on a scale from 0 to 100 and averaged. Higher scores indicate improved quality of life. The change from baseline in summed emotional, social, and school dimensions is presented.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline In PedsQL Multidimensional Fatigue Scale (MFS) Total Score At Month 6
units on a scaleCore Safety Follow-up Component
Change From Baseline In PedsQL Multidimensional Fatigue Scale (MFS) Total Score At Month 69.7 (9.7 to 9.7)
SecondaryPercentage Of Participants With Overly Rapid Correction In Serum Sodium 24 Hours After The First Dose At Introduction Or Reintroduction Of Tolvaptan

No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryPlasma Concentrations Of Tolvaptan And Metabolites In Participants Who Had Continued Tolvaptan Therapy For Eight Consecutive Weeks

No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected for this outcome measure.

Time frame:
8 Weeks

No measurements were reported for this outcome.

SecondaryParticipants With A Tanner Staging Score Of 1 At Month 6

Tanner Staging assessment consists of 2 domains (pubic hair and breast development) for girls and 3 domains (pubic hair, penis development, and testes development) for boys. Staging was based on a single score summarizing the domains (not individual domain scores). Stages range from 1-5, with 1 indicating preadolescent and 5 adult. Participants with a Tanner staging score of 1 (preadolescent) at Month 6 are reported.

Time frame:
Month 6
Reported as:
Count of participants · Participants
Participants With A Tanner Staging Score Of 1 At Month 6
ParticipantsCore Safety Follow-up Component
Participants With A Tanner Staging Score Of 1 At Month 62
SecondaryChange From Baseline In Growth Percentiles For Body Height And Weight At Month 6

Changes from baseline in growth percentiles for body height and weight were calculated and are reported.

Time frame:
Baseline, Month 6
Reported as:
Mean · percentile
Change From Baseline In Growth Percentiles For Body Height And Weight At Month 6
percentileCore Safety Follow-up Component
Height Percentile19.0 ± 40.0
Weight Percentile0.7 ± 8.0
SecondaryChange From Baseline In Alanine Aminotransferase (ALT) And Aspartate Aminotransferase (AST) For Participants On Tolvaptan At Month 2

No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected. Data reported only include assessments made for ALT and AST during the Core Safety Follow-up Component of the trial. Results are reported in units/liter (U/L).

Time frame:
Baseline, Month 2
Reported as:
Mean · U/L
Change From Baseline In Alanine Aminotransferase (ALT) And Aspartate Aminotransferase (AST) For Participants On Tolvaptan At Month 2
U/LCore Safety Follow-up Component
ALT-10.00 ± 45.25
AST-7.50 ± 0.71
SecondaryChange From Baseline In Bilirubin For Participants On Tolvaptan At Month 2

No enrolled participant received any investigational medicinal product during the study. Due to early study termination, efficacy data were not collected. Data reported only include assessments made for bilirubin during the Core Safety Follow-up Component of the trial. Results are reported in micromoles (umol)/L.

Time frame:
Baseline, Month 2
Reported as:
Mean · umol/L
Change From Baseline In Bilirubin For Participants On Tolvaptan At Month 2
umol/LCore Safety Follow-up Component
Change From Baseline In Bilirubin For Participants On Tolvaptan At Month 22.57 ± 3.63

Adverse events

Collected over Baseline to Month 6. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventTolvaptan
PyrexiaGeneral disorders1/3
Enterovirus InfectionInfections and infestations1/3
Rhinovirus InfectionInfections and infestations1/3
UrosepsisInfections and infestations1/3
Most frequent other events
Most frequent other events
EventTolvaptan
PyrexiaGeneral disorders1/3
BronchitisInfections and infestations1/3
Enterovirus InfectionInfections and infestations1/3
Rhinovirus InfectionInfections and infestations1/3
UrosepsisInfections and infestations1/3
Viral Upper Respiratory Tract InfectionInfections and infestations1/3

Baseline characteristics

All enrolled participants: No enrolled participant received any investigational medicinal product during the study. Due to the low number of participants enrolled, 0 participants are reported due to the risk of reidentification.

Age, Continuous
Age, Continuous(years)Tolvaptan
Sex: Female, Male
Sex: Female, Male(participants)Tolvaptan
Female—
Male—
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tolvaptan
Hispanic or Latino—
Not Hispanic or Latino—
Unknown or Not Reported—
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tolvaptan
American Indian or Alaska Native—
Asian—
Native Hawaiian or Other Pacific Islander—
Black or African American—
White—
More than one race—
Unknown or Not Reported—
08

Study locations

23 sites
  • Aurora, Colorado 80045, United States
  • Washington, District of Columbia 20010, United States
  • Atlanta, Georgia 30322, United States
  • Grand Rapids, Michigan 49503, United States
  • Kansas City, Missouri 64108, United States
  • Bronx, New York 10467, United States
  • New York, New York 10032, United States
  • Stony Brook, New York 11794-8111, United States
  • Cleveland, Ohio 44106, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Seattle, Washington 98105, United States
  • Gent, 9000, Belgium
  • Praha, 5 150 06, Czechia
  • Erlangen, Nurnberg, Germany
  • Leipzig, Sachsen 04289, Germany
  • Genova, 16147, Italy
  • Naples, 80131, Italy
  • Palermo, 90134, Italy
  • Rome, 00165, Italy
  • Bucharest, 022238, Romania
  • Sibiu, 550166, Romania
  • Madrid, 28007, Spain
  • London, WC1N 3JH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Small studies with less than 25 participants are excluded from data sharing.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Oct 2017, 18 months.

Results were first posted in Apr 2020, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2013
First posted
Dec 24, 2013
StartActual
Apr 22, 2016
Primary completionActual
Oct 23, 2017
CompletionActual
Oct 23, 2017
Results first posted
Apr 17, 2020
Last update
Apr 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02020278
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Dec 24, 2013
Start date
Apr 22, 2016
Primary completion
Oct 23, 2017
Completion
Oct 23, 2017
Results posted
Apr 17, 2020
Last update
Apr 17, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion